CBM588 in Improving Clinical Outcomes in Patients Who Have Undergone Donor Hematopoietic Stem Cell Transplant
Status:
Recruiting
Trial end date:
2021-12-24
Target enrollment:
Participant gender:
Summary
This pilot trial studies the side effects and how well CBM588 works in improving clinical
outcomes in patients who have undergone donor hematopoietic stem cell transplant. Gut
microbiota (formerly called gut flora) is the name given to the microbe (bacteria) population
living in the intestine. Gut bacteria help the body to digest certain foods that the stomach
and small intestine have not been able to digest. CBM588, may increase gut bacteria
biodiversity, prevent recurrent symptoms of gastrointestinal toxicity (ranging from diarrhea
to life-threatening inflammation of the colon).